Table 1.
Patients characteristics
| Case ID | Age range (years) | Invasive type | Molecular subtype | Histological type | Histological grade | Invasive nuclear grade | DCIS Nuclear grade |
DCIS type | ERf in DCIS | PRg in DCIS | Size (mm) | Th stage | Ni stage | Pathological clinical stage | Myriad test |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G1P1 | 50–60 | IDCa | Luminal B Her negativo | IDC | 3 | 3 | N | N | N | N | 31 | T2 | N0 | IIa | N > 50 |
| G1P2 | 50–60 | IDC | TNd | IDC | 3 | 3 | N | N | N | N | 10 | T1b | N0 | I | N > 50 |
| G1P3 | 60–70 | IDC | HER2 | IDC | 3 | 3 | N | N | N | N | 33 | T2 | N1 | IIb | N > 50 |
| G1P4 | 60–70 | IDC | Luminal A | IDC | 2 | 2 | N | N | N | N | 20 | T1c | N0 | I | N > 50 |
| G1P5 | 40–50 | IDC | Luminal B Her positivo | IDC | 1 | 1 | N | N | N | N | 40 | T2 | N0 | IIa | N < 50 |
| G1P6 | 40–50 | IDC | Luminal B Her negativo | IDC | 2 | 2 | N | N | N | N | 20 | T1c | N0 | I | N < 50 |
| G2P1 | 70–80 | Nb | N | DCISe | N | N | 3 | S, C, M, Co | ++++ | +++ | 105 | Tis | N0 | 0 | N > 50 |
| G2P2 | 40–50 | N | N | DCIS | N | N | 3 | S, C, M | – | – | 50 | Tis | N0 | 0 | N < 50 |
| G2P3 | 40–50 | N | N | DCIS | N | N | 3 | S, Co, C, M | +++ | +++ | 18 | Tis | N0 | 0 | N < 50 |
| G2P4 | 50–60 | N | N | DCIS | N | N | 3 | S, Co | ++++ | ++ | 30 | Tis | N0 | 0 | N > 50 |
| G2P5 | 50–60 | N | N | DCIS | N | N | 3 | C, M, Co | + | + | 60 | Tis | N0 | 0 | N > 50 |
| G2P6 | 50–60 | N | N | DCIS | N | N | 3 | S, M, Co | + | – | 20 | Tis | N0 | 0 | N > 50 |
| G3P1 | 50–60 | *IDCc | TN | DCIS-IDC | 3 | 3 | 3 | S, C, Co | – | – | 30 | T1c | N0 | I | N > 50 |
| G3P2 | 60–70 | *IDC | Her2 | DCIS-IDC | 3 | 3 | 3 | S, A, M, Co | – | – | 100 | T2 | N1 | IIb | N > 50 |
| G3P3 | 50–60 | *IDC | Luminal B Her negativo | DCIS-IDC | 3 | 3 | 3 | S, C, Co | ++++ | ++ | 65 | T1c | N0 | I | N > 50 |
| G3P4 | 60–70 | *IDC | Her2 | DCIS-IDC | 2 | 2 | 3 | S, C | – | – | 36 | T1a | N1 | IIa | N > 50 |
| G3P5 | 30–40 | *IDC | Luminal B Her negativo | DCIS-IDC | 2 | 2 | 2 | S, C | ++++ | + | 29 | T1a | N1 | IIa | N > 50 |
| G3P6 | 50–60 | *IDC | Luminal B Her positivo | DCIS-IDC | 3 | 3 | N | S, C, Co | ++++ | + | N | T1a | N0 | I | N > 50 |
DCIS type: S – solid; M – micropapillary; C – cribriform; A – adherent; Co – comedocarcinoma
Clinical stage as defined by TNM staging [10] metastases have always been absent, so the clinical stage is only extrapolated from T and N
Myriad’s hereditary cancer tests were made according Frank et al. [11] - N < 50 (family history of hereditary cancer absent and breast cancer diagnosed before 50 years of age) and > 50 (family history of hereditary cancer absent and breast cancer diagnosed after 50 years of age)
Histological grade was obtained according Lakhani et al. [12]. For ER and PR: stained slides were examined as follows: “negative” (−) - absence of brown precipitate in cells; the positive samples were labeled as (+) [if there were a few (< 10%) scattered cells with precipitate]; (++) [for large areas (10–50%) of positivity] and (+++) [designated 50 to 100% positivity]
IDC invasive ductal carcinoma
N not available or absent
DCIS-IDC IDC with in-situ component
TN triple negative
DCIS ductal carcinoma in situ
ER estrogen receptor
PR- progesterone receptor
T tumor
N regional lymph node